Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

ConclusionPembrolizumab demonstrated modest single agent activity in relapsed or refractory T-cell lymphoma.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research